Moreover, at the 12- and 18-month follow-up, there was a decrease in the levels of CSF tTau, pTau181, and NRGN. Between the two groups, there was no documented difference in CSF NFL. Comparing lecanemab to a placebo, the plasma exhibited a greater Aβ42/40 ratio, decreased pTau...